Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
Clinical Benefit
| Substantial |
The actual benefit of XELODA is substantial. |
Clinical Added Value
| no clinical added value |
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator. |
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
Ty65eYBHybXET6wd
